Our Clinical Trial Research

Members of the Division of Infectious Diseases conduct impactful, internationally recognized research in multiple realms of infectious diseases, epidemiology, global health, and health disparities research. Our specific strengths include basic and translational research in immunology, inflammatory response and invasive fungal infections, quality improvement, infection control, and community-partnered research to address health disparities in HIV and COVID-19.

We are partners in international COVID-19 and vaccine trials networks funded by the NIH and the Bill and Melinda Gates Foundation. Our clinical trials unit leads multiple clinical trials of therapeutic agents for COVID-19, fungal disease, and vaccines. Our learners, including infectious diseases fellows, residents, and students, are an integral part of our efforts as we foster the next generation of infectious diseases researchers.

Studies with Open Enrollment (Recruiting)

ACTIV-6

Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

RECOVER

Post Acute Sequelae of SARS-COV2 (PASC)

Cardiol

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Pending – Starting Soon

STOMP

Study of Tecovirimat for Human Monkeypox Virus

Closed to Enrollment – Ongoing

Novavax

Evaluating efficacy of 2-dose regiment of SARS-CoV-2 rS

Phase 1 mRNA HIV Vaccine Trial

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Completed Studies

ACTT

Adaptive COVID Treatment Trial

ACTIV-1 IM

Evaluate efficacy of Remdesivir

BET (ACTIV-5)

Evaluate clinical efficacy of Lenzilumab/Remdesivir vs placebo/Remdesivir

CAPA

COVID-19 Associated Pulmonary Aspergillosis

DISRUPT

Direct Lysis of Staph aureus Resistant Pathogen Trial

F2G

Open label olorofim

LYT-100

Also known as RECLAIN

Remdesivir Use in Kidney Failure

Evaluate efficacy of 5B-Lenzilumab/Remdesivir vs Placebo/Remdesivir

Repository

COVID-19 specimens

IAVI HIV Vaccine

Outpatient, phase 1 prevention

LANCER

CardiolRx in pts with COVID-19 & CVD or CVD Risk Factors

ReSTORE

Demonstrate Rezafungin for Injection

RLF-100

Aviptadil Study #1